Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
9 hedge funds and large institutions have $267K invested in Timber Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.
31% less funds holding
Funds holding: 13 → 9 (-4)
34% less capital invested
Capital invested by funds: $402K → $267K (-$135K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$101K |
| 2 |
Renaissance Technologies
New York
|
-$30K |
| 3 |
Bank of New York Mellon
New York
|
-$22.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$22.2K |
| 5 |
VF
Virtu Financial
New York
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $94K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $80.6K | -$101K | -61,261 | -65% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $48.1K | – | – | – |
|
4
State Street
Boston,
Massachusetts
| $35.1K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $7.11K | -$4.2K | -2,550 | -47% |
|
6
UBS Group
Zurich,
Switzerland
| $1.94K | -$8.76K | -5,323 | -87% |
|
|
CPG
7
Cornerstone Planning Group
Fairfield,
New Jersey
| $386 | +$262 | +159 | New |
|
|
8
Wells Fargo
San Francisco,
California
| $53 | +$3 | +2 | +10% |
|
|
SPIA
9
Steward Partners Investment Advisory
New York
| $2 | – | – | – |
|
|
10
Renaissance Technologies
New York
| – | -$30K | -17,700 | Closed |
|
|
11
Bank of New York Mellon
New York
| – | -$22.8K | -13,401 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$22.2K | -13,053 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$20K | -11,674 | Closed |
|
14
Barclays
London,
United Kingdom
| – | -$3.52K | -2,072 | Closed |
|
TMBR Hedge Fund Activity: Q2 2023 in Review
9 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2023, worth a combined $267K — down 34% from $402K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TMBR and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Wells Fargo, adding an estimated $3. The largest seller was Citadel Advisors, cutting an estimated $101K.
- 9 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $267K of Timber Pharmaceuticals, Inc. stock for Q2 2023, down 34% quarter-over-quarter.
- 1 fund opened new Timber Pharmaceuticals, Inc. positions in Q2 2023 and 5 closed out, a net change of -4 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2023 was Wells Fargo, an estimated $3 added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2023 was Citadel Advisors, an estimated $101K sold.
Based on aggregated 13F filings for Q2 2023.